Galapagos NV: business update: http://t.co/6w1jppWE
posted 6 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Ablynx [Euronext Brussels: ABLX] today announced a two-year extension of the initial five-year research funding by Boehringer Ingelheim of their global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics. The extension which will run until September 2014, will allow all the existing ten Nanobody programmes to advance to a stage where Boehringer Ingelheim can potentially progress each programme into development. Ablynx will receive a total of €6.6 million in additional research funding from Boehringer Ingelheim, some of which will be in advance. This payment is in return for work carried out by Ablynx's specialist Nanobody scientists. Ablynx has already received over €58 million from payments under the Strategic Alliance since it was signed in 2007. read more
The Hagen Desert Farming Project (HDFP), a humanitarian initiative designed for the most environmentally challenged northern states in Nigeria and the industrial crop technology company, QUINVITA announced today they have entered into a major strategic Jatropha development alliance. Under the signed agreement, as a member of the QUINVITA knowledge platforms for breeding, cultivar development and agronomy, HDFP will access the QUINVITA PRO (QVP) seed cultivars for planting in the project. Both companies agree that this relationship will provide the basis for an extensive collaboration on the testing and demonstration of different Jatropha lines, especially selected for adaptation to West‐Africa and appropriate agronomy, applicable by out‐growers who will be engaged by the HDFP. read more
Galapagos NV (Euronext: GLPG) announced today that investigational medicine GLPG0778, which is part of its immuno-inflammatory alliance with GlaxoSmithKline, has shown selective effects on a biomarker in a Phase I Proof-of-Mechanism study in healthy volunteers. The study also provided information on the safety and pharmacokinetic (PK) profile of GLPG0778. read more
Servier, a leading French pharmaceutical company, and Galapagos NV (Euronext: GLPG) announced today that they have entered into a multi-year strategic alliance to develop new therapies in osteoarthritis (OA). read more
FlandersBio, de Vlaamse sectororganisatie voor de life sciences en biotechnologie en de Amerikaanse biotechcluster Bio New Jersey (BioNJ) ondertekenden vorige week een samenwerkingspact met als doel hun activiteiten voor de sector samen af te stemmen. De ondertekening gebeurde in aanwezigheid van verschillende Vlaamse biotechbedrijven en vond plaats in Chicago tijdens BioUS, de grootste biotechbeurs ter wereld waar 15 322 biotechspelers van 49 staten en 65 landen vertegenwoordigd waren. read more
Galapagos NV (Euronext: GLPG) announced today that it has entered into a global multi-year strategic alliance with Roche (SIX: RO, ROG; OTCQX: RHHBY) to develop potential new therapies in COPD (chronic obstructive pulmonary disease). read more
Galapagos NV (Euronext: GLPG) announced today that it has expanded its arthritis alliance with GlaxoSmithKline (LSE & NYSE: GSK) to include additional drug discovery programs based on novel drug target GT622. read more
Galapagos NV (Euronext: GLPG) announced today that it has initiated clinical Phase I development of the first small molecule candidate from its arthritis alliance with GlaxoSmithKline (GSK). read more
The world’s first concept demonstration tires made with BioIsoprene™ technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of synthetic rubber with renewable biomass, made their debut in Copenhagen, Denmark, this week. read more
reMYND NV (‘reMYND’) announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough (NYSE ticker: SGP) for the supply and use of RadarScreen, a novel yeast-based screening system that allows the rapid and cost-effective identification of genotoxic compounds in early stage drug discovery. read more
